Novavax Inc vs Carparts.Com Inc — how do they compare? Novavax Inc trades at $8.11 (market cap $1.30B), while Carparts.Com Inc trades at $5.09 (market cap $41.22M). The key difference: Novavax Inc is far larger — about 31.5× Carparts.Com Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Carparts.Com Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | PRTS | |
|---|---|---|
Market Cap | $1.30B | $41.22M |
Sector | Health | Consumer Cyclical |
52-Week High | $11.19 | $11.40 |
52-Week Low | $6.22 | $3.88 |
Enterprise Value | $800.50M | $56.19M |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
PRTS trades at $4.85, down 8.49% today, reflecting a bearish technical trend. The company reported a net loss of $50.44M in 2025 despite revenue of $547.53M, with negative cash flow from operations. Recent developments include a reverse stock split and a new $25M credit facility, while analysts maintain a 60% buy rating. The stock shows oversold conditions with RSI levels below 30, indicating potential for a near-term bounce.
The outlook remains challenging due to persistent losses and negative cash flow, though cost-cutting measures and recent earnings beats offer some optimism. Key risks include execution on profitability and competitive pressures. The stock presents a high-risk opportunity for investors betting on a turnaround, supported by analyst bullishness but tempered by fundamental weaknesses.
Trailing returns across standard periods
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →